Baharan Meghdadi

Baharan Meghdadi

Auto-generated profile, based on publicly available information

Baharan Meghdadi

University of Michigan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2025 in Nature
Verified
Journal Article
Open access
PDF file
ASAndrew J. Scott
Andrew J. Scott
AMAnjali Mittal
Anjali Mittal
BMBaharan Meghdadi
Baharan Meghdadi
AOAlexandra O’bRien
Alexandra O’bRien
JBJustine Bailleul
Justine Bailleul
Daniel R. WahlDaniel R. Wahl
Daniel R. Wahl
The brain avidly consumes glucose to fuel neurophysiology1. Cancers of the brain, such as glioblastoma, relinquish physiological integrity and gain the ability to proliferate and invade healthy tissue2. How brain cancers rewire glucose use to drive aggressive growth remains unclear. Here we infused 13C-labelled glucose into patients and mice with brain cancer, coupled with quantitative metabolic flux analysis, to map the fates of glucose-derived carbon in tumour versus cortex. Through direct and comprehensive measurements of carbon and nitrogen labelling in both cortex and glioma tissues, we identify profound metabolic transformations. In the human cortex, glucose carbons fuel essential physiological processes, including tricarboxylic acid cycle oxidation and neurotransmitter synthesis. Conversely, gliomas downregulate these processes and scavenge alternative carbon sources such as amino acids from the environment, repurposing glucose-derived carbons to generate molecules needed for proliferation and invasion. Targeting this metabolic rewiring in mice through dietary amino acid modulation selectively alters glioblastoma metabolism, slows tumour growth and augments the efficacy of standard-of-care treatments. These findings illuminate how aggressive brain tumours exploit glucose to suppress normal physiological activity in favour of malignant expansion and offer potential therapeutic strategies to enhance treatment outcomes.

30 January 2026 in Cancer Prevention Research
Verified
Journal Article
Open access
FWFrank Weinberg
Frank Weinberg
Abhinav AchrejaAbhinav Achreja
Abhinav Achreja
ARAmrita Roy
Amrita Roy
OAOlamide Animasahun
Olamide Animasahun
BMBaharan Meghdadi
Baharan Meghdadi
DNDeepak Nagrath
Deepak Nagrath
Lung cancer is the leading cause of cancer-related deaths. The human microbiome plays an important role in regulating response to cancer therapeutics, outcomes, and biological processes. However, little is known about the interplay between the lung microbiome and other biological processes in cancer. In an exploratory pilot study, we collected bronchoalveolar lavage fluid and brushings from 20 patients with early-stage lung cancer and performed microbial sequencing, untargeted metabolomics, and cytokine analysis. In addition, we employed computational and machine learning approaches to identify integrated microbial–immunometabolic pathways. Finally, we performed preliminary mechanistic studies to confirm our findings. Previously, we published that upper airway microbiota were selectively enriched in tumor-affected lobes. In the present study, we demonstrate that enrichment of protumorigenic cytokines and specific fatty acids is associated with tumor-affected lobes. Finally, we find that long-chain fatty acid stimulation of macrophages leads to neoplastic transformation of lung epithelial cells. Therefore, the findings of this study identify a perturbed fatty acid–macrophage axis that is a potential biomarker of early-stage lung cancer and will lead to the development of novel therapeutic agents. Prevention Relevance: This study identifies a lung microbiome-driven immunometabolic axis involving stearic acid and MIP1β in tumor-affected lobes of patients with early-stage lung cancer. These localized microbial and cytokine–metabolite signatures may serve as biomarkers for early detection and provide targets for preventive strategies in high-risk individuals undergoing lung cancer screening.

1 April 2026
Verified
Other
Open access
FWFrank Weinberg
Frank Weinberg
Abhinav AchrejaAbhinav Achreja
Abhinav Achreja
ARAmrita Roy
Amrita Roy
OAOlamide Animasahun
Olamide Animasahun
BMBaharan Meghdadi
Baharan Meghdadi
DNDeepak Nagrath
Deepak Nagrath
Supplementary Figure S5 shows principal component analyses indicating separation between tumor and unaffected lobes, including elbow plots, PCA training, and loading distributions for PC1 and PC2.

1 April 2026
Verified
Other
Open access
FWFrank Weinberg
Frank Weinberg
Abhinav AchrejaAbhinav Achreja
Abhinav Achreja
ARAmrita Roy
Amrita Roy
OAOlamide Animasahun
Olamide Animasahun
BMBaharan Meghdadi
Baharan Meghdadi
DNDeepak Nagrath
Deepak Nagrath
Supplementary Figure S8 shows association plots between microbial taxa (OTUs) and metabolites in unaffected lobes.

1 April 2026
Verified
Other
Open access
FWFrank Weinberg
Frank Weinberg
Abhinav AchrejaAbhinav Achreja
Abhinav Achreja
ARAmrita Roy
Amrita Roy
OAOlamide Animasahun
Olamide Animasahun
BMBaharan Meghdadi
Baharan Meghdadi
DNDeepak Nagrath
Deepak Nagrath
Supplementary Figure S12 shows qPCR analysis of MIP1α and MIP1β expression in cancerous and non-cancerous cell lines under vehicle and stearic acid treatment.

1 April 2026
Verified
Other
Open access
FWFrank Weinberg
Frank Weinberg
Abhinav AchrejaAbhinav Achreja
Abhinav Achreja
ARAmrita Roy
Amrita Roy
OAOlamide Animasahun
Olamide Animasahun
BMBaharan Meghdadi
Baharan Meghdadi
DNDeepak Nagrath
Deepak Nagrath
Supplementary Figure S2 shows the agar layer setup used in the anchorage-independent colony formation assay.